Understanding the Limitations of Medicare's Pricing Model for State Drug Policies A recent study critiques the application of Medicare's Maximum Fair Price model to state drug pricing, highlighting potential conflicts and patient access problems.

Understanding the Limitations of Medicare's Pricing Model for State Drug Policies #United_States #Washington #Patient_Access #Rare_Access_Action #Medicare_Drug_Pricing

New Study from RAAP Reveals Challenges of Prescription Drug Affordability Boards The Rare Access Action Project unveils a critical study highlighting the inefficacy of Prescription Drug Affordability Boards, offering alternative solutions for rare disease drug access.

New Study from RAAP Reveals Challenges of Prescription Drug Affordability Boards #USA #Washington #Prescription_Drugs #Rare_Access_Action #PDAB